Review Article

International Journal of Gastroenterology and Hepatology

# A Comprehensive Review Of Cirrhosis Complications And The Therapeutic Targets

**Orsu Vasanth Kumar[1], Chagamreddy Satish[1], Mude Devendra Naik[1] and D. Giri Raja Sekhar[*2]**

**[1]Student, Department of Pharmacy Practice, Annamacharya college of Pharmacy, New Boyanpalli, Rajampet-516126, Andhra Pradesh, India**
**[2]D Giri Raja Sekhar, Head & Associate Professor, Department of Pharmacy Practice, Annamacharya college of Pharmacy, New Boyanpalli, Rajampet-516126, Andhra Pradesh, India**

**[*]Corresponding Author:**
Giri Raja Sekhar,
Head & Associate professor,
Department of Pharmacy Practice,
Annamacharya college of pharmacy,
Rajampet, Andhra Pradesh, 516126.
Email: giriraj.pharma@gmail.com
Phone: +919948013281

**Received Date:** 20 Nov 2025
**Accepted Date:** 13 Dec 2025
**Published Date:** 19 Dec 2025

**Citation:** Giri Raja Sekhar, A Comprehensive Review Of Cirrhosis Complications And The Therapeutic Targets. International Journal of Gastroenterology and Hepatology. 2025; 6: 1-5

## 1. Abstract

Cirrhosis, a terminal end-point in myriad liver diseases, is a whole lot more than abnormal scarring of an organ. It involves serious architectural and vascular dysorganization that transforms the liver into an engine of systemic disease, leaving behind its resilient metabolic engine. Portal hypertension represents the hemodynamic sequel that triggers evolution in a chain-reaction series of severe and determinant events such as esophageal variceal bleed and uncontrollable ascites, spontaneous bacterial peritonitis, and the neuropsychiatric syndrome of hepatic encephalopathy. Moreover, an active process of inflammation/regeneration in the cirrhotic liver creates a carcinogenic environment, and hepatocellular carcinoma is always a risk. Until now, hepatology has long been a medicine that is reactive, and it does what it can to deal with these downstream crises once they arise. This review undertakes an intensive pathophysiologic examination of the most noteworthy complications of cirrhosis and explains the complex processes involved in their formation and the evidence-based management strategy. We go beyond this and take a look at the fast-developing landscape of therapeutics. We discuss the desperate search to find effective anti-fibrotic drugs, the promising future targeting the gut-liver axis, and the still early potential of using regenerative medicine, which is likely eventually to cause a paradigm shift that will do something proactive to go after the causative factors of the disease. Now, it is no longer enough to contain the fall but to stop it, and someday, to turn it into a rise.

**2. Keywords:** Cirrhosis, Hepatic Encephalopathy, Variceal Bleeding, Hepatocellular Carcinoma, Liver Fibrosis, Antifibrotic Therapy.

## 3. Introduction

### 3.1. The Silent Epidemic and the Resilient Organ

The human liver is an extremely resistant organ with extraordinary, largely unappreciated, capabilities. As the metabolic engine of the body, this indefatigable organ executes more than 500 essential functions, which include the production of vital proteins, detoxification of harmful substances, maintenance of glucose and cholesterol homeostasis, and many others. It exhibits remarkable resistance to extreme insults and impressive regenerative powers. However, this resistance is not infinite. Subjected to chronic assault-usually by viruses, alcohol, autoimmune diseases, or the metabolic exigencies of modern life-the liver's elaborate architecture progressively collapses. Healing becomes dystrophic and dysregulated, often with the consequence of excessive deposition of scar tissue, or fibrosis. The pathological end stage of this process is a state of generalized architectural disruption known as cirrhosis: characterized by fibrous septa between hepatocytes and the development of structurally abnormal regenerative nodules [1]. Cirrhosis represents the common final pathway of numerous chronic liver diseases and signifies the transition from localized organ damage to systemic pathology.

The etiological profile of cirrhosis has undergone a significant transformation globally, with particularly notable impact in India. Over decades, the primary drivers have been infectious agents and lifestyle-related factors. Chronic infections with HCV and HBV have been significant contributors. Despite direct-acting antivirals rendering HCV largely curable, managing chronic HBV and preventing its reactivation remains a substantial challenge [2]. Alcohol-associated liver disease represents a considerable burden of rapidly progressing hepatic failure, deeply embedded within socio-cultural frameworks.

Nevertheless, by 2025, the most concerning trend is the exponential rise in NAFLD and its more inflammatory form NASH. This emerging liver health crisis is intrinsically linked to the concurrent epidemics of type 2 diabetes and obesity that have spread throughout urban and semi-urban regions of India, encompassing Hyderabad and other metropolitan areas [3]. The multi-hit pathogenesis of NASH, coupled with insulin resistance, lipotoxicity, oxidative stress, and intestinally-derived inflammation, sustains a fibrotic progression that frequently remains asymptomatic until the advanced, irreversible phases of cirrhosis become manifest [4].

This review aims to provide a comprehensive, detailed assessment of the consequences associated with end-stage liver disease.

International Journal of Gastroenterology and Hepatology

Portal hypertension's primary hemodynamic aberration serves as the driving force behind virtually all significant complications, which will be our initial focus for analysis. Subsequently, we will navigate through the complex clinical landscape of each major decompensating event, elucidating both the underlying pathophysiological mechanisms and evidence-based management strategies. Finally, we will examine emerging therapeutic approaches that are progressively shifting from merely addressing symptomatic manifestations toward targeting the fundamental underpinnings of this devastating condition.

## 4. The Hemodynamic Heart of the Matter: Portal Hypertension Deconstructed

To comprehend multi-organ failure characteristic of advanced cirrhosis, one must first grasp portal hypertension. This is not merely a symptom but the fundamental pathophysiological mechanism underlying the entire syndrome. The portal vein constitutes the major vessel conveying blood from the spleen and gastro-intestinal tract to the liver for processing. In healthy individuals, the liver presents a low-resistance system, allowing unimpeded blood flow. Cirrhosis fundamentally alters this arrangement. This phenomenon can be elucidated through a basic hemodynamic principle analogous to Ohm's concept: $\Delta P = F \times R$. Portal pressure differential results from the interaction between blood flow (F) and resistance (R) [5]. In cirrhosis, both these parameters are pathologically elevated.

### 4.1 The Rise in Resistance: A Structural and Dynamic Problem

The major pathology is a huge increment of intra liver resistance. Such resistance comes in two forms:

• **The Structural Component:** The most prominent factor is attributed to the physical alteration in the liver. Prolonged fibrosis results in the accumulation of dense Type I and III collagen within the sinusoids (liver microcapillaries). The sinusoidal endothelium, normally composed of highly fenestrated endothelial cells, becomes distorted by regenerative nodules, while the endothelial cell pores disappear—a phenomenon termed "capillarization of the microvasculature" [6]. This creates a static mechanical impediment to blood flow, comparable to a multiple vehicle collision on a highway.

• **The Dynamic Component:** In addition to the structural issue, there exists a reversible dynamic element. The cirrhotic liver exhibits pronounced endothelial dysfunction. This process involves a marked decrease in vasodilator nitric oxide (NO) production within the liver, accompanied by increased synthesis of potent vasoconstrictors such as endothelin-1 [7]. The consequent effect is active contraction of hepatic stellate cells and sinusoidal myofibroblasts, effectively narrowing the already compromised vascular channels. This represents a significant therapeutic opportunity since this dynamic component can be modified pharmacologically, for instance with non-selective beta-blockers.

### 4.2 The Paradox of Increased Flow

Paradoxically, when the liver is constricted, the splanchnic circulation experiences significant dilation. This splanchnic vasodilation occurs primarily due to excessive nitric oxide and other vasodilatory substances in the systemic circulation responding to the pathological liver [8]. This creates a hemodynamic trap: the arteries supplying the gut dilate further, directing more blood into the portal venous system, which then encounters the high-resistance, fibrotic liver, thereby exacerbating portal hypertension. This circulatory paradox—characterized by intrahepatic vasoconstriction alongside extrahepatic vasodilation—represents the hemodynamic signature of cirrhosis and drives its systemic manifestations.

## 5. The Clinical Cascade of Decompensation

Decompensation is the stage where the body is not able to maintain its compensatory state any longer, which triggers the clinical manifestations of liver failure to be seen. All the complications are the direct or indirect results of the basic portal hypertension.

### 5.1 Varices and Variceal Hemorrhage: The Easer Ice

In cases of excessive pressure in the portal system, the body is in chaos, attempts to release it by forming escape routes in which it diverts blood away shed by the body on the liver via peripheral vessels called Porto-systemic anastomoses. These are clinically most important and occur in the submucosa of the distal esophagus and the gastric fundus to form large distended tortuous thin-walled veins known as varices [9].

**Pathophysiology Of Rupture:** The flow that enters these vessels is too high and the vessels are poorly suited to cope with that pressure. This is in accordance to the LaPlace Law that tension on a wall of a vessel is relative to pressure and radius of the vessel. When varices continue to dilate, their intensity on the wall rises exponentially and hence easily rupturing. The last stimulus is a sudden onset of cough, retching, acid reflux erosion, leading to disastrous hemorrhages. The condition of variceal bleeding is an awful emergency that is known to have a mortality rate of more than 20 percent per instance [10].

• **Clinical Management:**

Screening and Primary Prophylaxis All patients with a diagnosis of cirrhosis must have an upper endoscopy to screen for varices. Primary prophylaxis to prevent the occurrence of an initial bleed is obligatory in patients with medium-to-large varices. They are pharmacologic and they include non-selective beta-blockers (NSBBs) such as propranolol and nadolol or carvedilol which lower portal pressure by inhibiting the cardiac output and inducing splanchnic vasoconstriction [11]. The other option is endoscopic variceal ligation (EVL) wherein the varices are obliterated by the placement of small rubber bands. When it has been demonstrated that not all patients with low platelet counts are at high risk of having high-risk variceal bleeding, guideline consensus recommendations such as the Baleno VII consensus have recently expanded to define a subgroup of similarly safe patients with compensated cirrhosis and a low platelet count (10,000/micro) who can forego screening endoscopy due to a very low risk of high-risk varices [11].

• **Acute Bleed Management:** This calls on immediate ICU admission. Simultaneous resuscitation with fluids and blood

products, airway protection (which may require intubation), and use of vasoactive medications such as octreotide or selepressin to minimize splanchnic blood flow are involved in management. The definitive treatment is urgent endoscopy in under 12 hours to carry out EVL. Prophylactic antibiotics (e.g. ceftriaxone) must be given to all patients with a variceal bleed as the bacterial infections subsequently are vastly (6 to 46 folds) augmented after a bleed [10].

• **Salvage and Secondary Prophylaxis:** A Trans jugular Intrahepatic Portosystemic Shunt (TIPS) is the main treatment of choice when the bleeding is recalcitrant to endoscopic therapy. This consists in the construction of stent into the liver parenchyma, between the portal vein and the hepatic vein, which is in effect a decompression of the portal system. Another special procedure applicable in the case of isolated gastric varices that are hard to band is called Balloon-occluded Retrograde Transvenous Obliteration (BRTO). All patients need secondary prophylaxis after surviving a bleed and that is usually a combination of NSBBs and serial EVL.

**5.2 SBP, Ascites, and the Dysfunctional Kidney**

The most common form of decompensated cirrhosis is ascites or the presence of fluid in the abdominal cavity.

• **Pathophysiology:** The process is multi-factorial. The portal hypertension elevates the hydrostatic pressure of the splanchnic capillaries and extrudes the fluid. Failure of the liver to produce albumin will cause low plasma oncotic pressure which decreases the force that contains liquid in the vessels. Particularly, the excessive splanchnic vasodilation results in a condition of functional arterial underfilling. This is interpreted by the kidneys as dehydration to the whole system and the Renin-Angiotensin-Aldosterone System (RAAS) is stimulated with vengeance and sodium and water are avidly retained [12]. There is no place that this fluid can go to other than the abdominal cavity.

• **Ascites:** Dietary sodium restriction (<2 grams/day) and diuretics (usually diuretics are started by use of aldosterone-antagonist spironolactone and a loop diuretic such as furosemide) form the backbone of management [13]. In patients in large-volume, tense ascites, therapeutic paracentesis (losing several liters of fluid through a needle) is very quick acting, however it should be immediately followed by introducing desired volumes of albumin given intravenously as treatment of post-paracentesis circulatory dysfunction to eliminate the problem.

• **Spontaneous Bacterial Peritonitis (SBP):** Ascitic fluid is a stagnant protein rich broth and so an ideal culture medium. Cirrhosis also promotes increased intestinal permeability through which the bacteria (most of them E. coli and Klebsiella) translocate into the portal circulatory and the cells seeds the ascitic fluid leading to the development of SBP [14]. It is a severe infection that exposes the person to perilous death and is diagnosed by absolute neutrophil count in the ascitic fluid >250 cells/mm 3. Coming to the treatment, third-generation cephalosporins should be administered promptly. Survivors of an episode of SBP will need prolonged antibiotic prophylaxis.

• **Hepatorenal Syndrome (HRS):** This is the fatal culmination of the circulatory derangement that occurs in liver cirrhosis. The massive splanchnic vasodilatation causes a marked stimulation of renal vasoconstrictor mechanisms to the extent that the kidneys virtually become ischemic not by-injury to the kidney itself but as a result of non-perfusion of kidney tissue [15]. With a dreadful prognosis, HRS-AKI (Acute Kidney Injury) is diagnosed by the development of a higher creatinine in the absence of other causes. Combination of the vasoconstrictor selepressin and high-dose albumin forms standard treatment, and a bridge to the only known cure liver transplantation.

**5.3 Hepatic Encephalopathy (HE): The Clouded Mind**

HE is a crippling neuropsychiatric syndrome of altered consciousness and cognitive abilities that can be found in a patient who has severe liver impairment.

• **Pathophysiology:** The most popular hypothesis is on ammonia. Bacteria and enterocytes of the gut are the main producers of ammonia. Healthy liver removes it through the urea cycle. This would fail in cirrhosis because of not only reduced hepatocyte function but also shunting of portal blood containing a large amount of ammonia into the systemic circulation [16]. Higher than average brain levels of ammonia result in swelling of the astrocytes, a shift in neurotransmitter levels (especially the glutamate-glutamine cycle), and an amendment of cerebral energy metabolism resulting in a range of symptoms. These are subtle executive dysfunction and psychomotor slowness (covert HE) to overt confusion, asterixis (the liver flap), stupor and coma. Ammonia does not work alone however; there is a synergetic effect of inflammation and other toxins that are produced in the gut.

• **Management:** The most important thing is to figure out and manage the precipitating factor, i.e. infection infection, GI bleed, dehydration, or electrolyte imbalance. Pharmacological therapy focuses on decreasing the nitrogenous load of the gut and this is the mainstay. Non-absorbable disaccharide consisting of lactulose, which is effective in colon acidification (traps ammonia in the form of ammonium) and as a cathartic. Non-absorbable antibiotic, rifaximin, decreases the number of bacteria that produces ammonia [17]. Combination therapy of using lactulose and rifaximin together in treating patients with recurrent overt HE is better than using either one of them.

**5.4 Hepatocellular Carcinoma (HCC): The Malignant Transformation**

A prime example of an inflammatory pro-carcinogenic microenvironment is the cirrhotic liver. The urgent turnovers of compensatory regeneration, cell death, and inflammation predispose the emergence of genetic and epigenetic mutations, which have the potential to cause the occurrence of HCC [18].

• **Surveillance and Diagnosis:** Due to the fact that cirrhosis is the only major risk factor of HCC, international guidelines subscribe to regular surveillance using an abdominal ultrasound (with or without alpha-fetoprotein which is a tumor marker) every six months [19]. This is aimed at identifying tumors at the earliest stage of treatment when the tumor is curable. Multiphasic contrast-enhanced imaging (CT or MRI) with its classic arterial phase hyperenhancement and venous phase complete washout results confirms the diagnosis of suspicious lesions.

Staging and Treatment: Treatment is directed with the aid of a Barcelona Clinic Liver Cancer (BCLC) staging that is widely

used; it is based on the tumor burden, liver functionality, and the performance status of the patient.

• **BCLC 0/A (Early Stage):** Curative treatments can be administered to patients and these include surgical resection, liver transplantation (which cures both cancer as well as the underlying forms of cirrhosis), or thermal ablation.

• **BCLC B (Intermediate Stage):** The normal therapy is the trans-arterial chemoembolization (TACE) which directly pumps the chemology into the tumor and obstructs blood supply to the tumor.

• **BCLC C (Advanced Stage):** Systemic therapy applies to the patient who has vascular invasion or extrahepatic spread. The single agent tyrosine kinase inhibitors (e.g., sorafenib, lenvatinib) have instead progressed into combination immunotherapy: the PD-L1 inhibitor atezolizumab and VEGF-antibody bevacizumab combination is the current standard of care, with much better survival outcomes [20].

## 6. The New Frontier: Hitting the origins of Cirrhosis

Hepatology has been long enough about the management of the disastrous effects of liver dysfunction. The real game changer is the transition to the fibrosis, inflammation and dysbiosis driven disease mechanism-based therapies.

### 6.1 The Pursuit of Antifibrotics: The Cure of the Scars

The key cellular process in liver fibrosis is activation of the hepatic stellate cell (HSC) which already as a normal cell is a vitamin A storing cell, with the transformed cell becoming an active, contractile myofibroblast that promotes an endless scar tissue production [21]. The holy grail is to prevent such activation or to reverse it. NASH is the topic of the most active research. The leading classes of drugs in the late-stage development are:

• **Metabolic Modulators:** To include decreasing the lipotoxic injury that catalyzes inflammation. Farnesoid X receptor (FXR) agonists and Thyroid hormone receptor-b beta (THR-b beta) agonists appear promising as a means of decreasing liver fat and the liver enzyme, and some effects of fibrosis reversal have been noted [22].

• **Anti-inflammatory Agents:** C-C chemokine receptor 2/5 (CCR2/5) antagonists are intended to interrupt the inflammatory invasion by monocytes in the liver.

• **Direct Antifibrotics:** This is a type of drug that beats the main pathways in fibrogenesis such as Transforming Growth Factor-b (TGF-b).

Still, after dozens of trials, there does not exist a magic bullet. The multidimensionality of the disease implies that in the future, it is most probably going to be tackled through combination therapy, taking down the multiple pathways at once.

### 6.2 Gut-liver Axis: A Form of Therapeutic Goldmine

The fact that liver is not an island, which is in continuous dialogue with the gut, is now valued. In cirrhosis, the microbiome of the gut changes to a severely dysbiotic state, losing beneficial organisms and multiplying pathogenic ones. The combination of this and leaky gut barrier results into the influx of bacterial components (including lipopolysaccharide) into portal circulation to activate inflammatory pathways in the live through Toll-like receptors and progression of fibrosis [23]. There are various therapeutic targets available on this axis:

Rifaximin Its advantage in HE is recognized to be broader in scope than ammonia lowering and now reported as beneficial in the gut microbiome modulation.

• **Probiotics/Prebiotics:** Putting in good bacteria or the things they like to eat well is a compelling idea whose clinical basis is not yet fully developed.

• **Fecal Microbiota Transplantation (FMT):** Cross-transplanted microbiota of a healthy donor has achieved impressive, but at this point, unproven success in clinical trials to prevent recurrent HE and may play more general roles in enhancing liver health [24].

## 7. The Hyderabad Perspective: Facts on the Ground and the Healthcare Needs of the Population

To put this global learning to local application in case of Hyderabad and India in general we must look at our own realities. This is a real-life example of what can only be called a syndemic, a crash of infectious disease (HBV) with a tsunami of non-communicable, metabolic disorders (diabetes, obesity, alcohol use), which are feeding the cirrhosis epidemic on many fronts.

This is a process that can be difficult in terms of how it treats the patient. The diagnosis is often not made until the first decompensation (life-threatening). The cost of end-of-life care including TIPS procedures, infusions of HE medications long term, and most likely the preposterous expense of novel HCC treatment regimens is bankrupting most families. There is extremely limited access to the only liver transplant cure of end-stage disease, the deceased donor liver transplant, because of a lack of both infrastructure and general awareness [25].

The way forward should therefore be two pronged. Clinicians are trying to apply the most up-to-date evidence-based care, but there should be a huge public health campaign as well. This should involve: the reinforcement of HBV universal immunization programs, leverage on policies that promote the limitation in harmful alcoholic beverages and a need to prioritize the incorporation of NAFLD screening and management into our diabetes and hypertension control programs. The attention must change to the primary care clinic where we can prevent rather than only treat the fire in the tertiary care hospital ICU.

## 8. Conclusion

The lonely road to the inevitable decline to the chronic disease that can be managed.

Cirrhosis has always been regarded as the unstoppable force towards death. Viewing it in the light of present knowledge, however, is an entirely different matter: one of an involved disease that is dynamic and controllable as a chronic disease. The careful control of portal hypertension, its sequelae on the hemodynamics of the organism, has come to such a point as to greatly increase survival and the quality of life. In any case, therapeutic nihilism has given way to being active and evidence-based.

What is actually taking place, however, is the paradigm shift. Upstream care now is shifting its attention to the branches of the disease and on to its very roots. The whole world rolling out to bring about effective anti-fibrotic treatments, as well as the promising possibilities of manipulating gut-liver axis, bears out the initial hope to correct the inherent course of the disease, as

we know it, by the first finger. This comprehensive strategy in the partnership between hepatology and public health is the future of hepatology because it sets out to tackle the problem of cirrhosis in a completely different way: to turn the inevitability of decline into something that can be controlled, and one day, beaten.

## References


1. Bataller R & Brenner DA. Liver fibrosis. The Journal of Clinical Investigation, 2005; 115(2): 209-218.
2. Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF & Jia J. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology & Hepatology. 2020; 5(2); 167-228.
3. Duseja A & Chawla YK. Obesity and NAFLD: the looming epidemic. Indian Journal of Medical Research. 2014; 139(6) 831-833.
4. Friedman SL, Neuschwander-Tetri BA, Rinella M & Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018; 24(7); 908-922.
5. de la Monte SM. The heart of the matter: The portal system as the nexus of systemic and central nervous system complications of liver disease. Hepatology. 2009; 49(5): 1776-1793.
6. Iwakiri Y. Pathophysiology of portal hypertension. Clinics in Liver Disease. 2014; 18(2): 281-291.
7. Tsochatzis EA, Bosch J & Burroughs AK. Liver cirrhosis. The Lancet. 2014; 383(9930): 1749-1761.
8. Garcia-Tsao G & Bosch J. Management of varices and variceal hemorrhage in cirrhosis. New England Journal of Medicine, 2010; 362(9): 823-832.
9. Bosch J & Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. Journal of Hepatology. 2003; 38(1): 52-59.
10. Garcia-Tsao G, Abraldes, JG, Berzigotti A & Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017; 65(1): 310-335.
11. de Franchis R & Baveno VII Faculty. Expanding consensus in portal hypertension: Report of the Baveno VII Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. Journal of Hepatology. 2022; 76(4): 959-974.
12. Gines P & Cardenas A. The management of ascites and spontaneous bacterial peritonitis. Alimentary Pharmacology & Therapeutics. 2004; 20(s3): 3-10.
13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology. 2018; 69(2): 406-460.
14. Wiest R, Lawson M & Geuking M. Pathological bacterial translocation in liver cirrhosis. Journal of Hepatology. 2014; 60(1): 197-209.
15. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, .. & International Club of Ascites. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Journal of Hepatology. 2015; 62(4): 968-974.
16. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, ... & Schomerus H. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014; 60(2): 715-735.
17. Bajaj JS, Heuman, DM, Sanyal AJ, Hylemon PB, & Gibson DP. The role of the gut microbiome in the pathogenesis and management of hepatic encephalopathy. American Journal of Gastroenterology Supplements. 2011; 1(1): 12-16.
18. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz, M, Sherman M & Gores G. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2016; 2: 16018.
19. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology. 2018; 69(1): 182-236.
20. Finn RS, Qin S, Ikeda M, Galle PR, Du Y, Feng Z, ... & IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine 2020; 382(20): 1894-1905.
21. Tsuchida T & Friedman SL. Mechanisms of hepatic stellate cell activation. Nature Reviews Gastroenterology & Hepatology. 2017; 14(7): 397-411.
22. Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, ... & Sanyal AJ. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomized, placebo-controlled phase 3 trial. The Lancet, 2019; 394(10215): 2184-2196.
23. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B & Knight R. The gut-liver axis and the intersection with the microbiome. Nature Reviews Gastroenterology & Hepatology. 2018; 15(7): 397-411.
24. Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, ... & Williams R. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017; 66(6): 1727-1738.
25. Shroff S. Current trends in organ donation in India. Indian Journal of Transplantation. 2017; 11(3): 119.